Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil

Obesity is among the most alarming health concerns, impacting public health and causing a socioeconomic challenge, especially in developing countries like Brazil, where approximately one quart of the population presents obesity. As an established risk factor for numerous comorbidities with a multifa...

Full description

Bibliographic Details
Main Authors: Ligia M. Watanabe, Anderson M. Navarro, Lucia A. Seale
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/13/6/2027
_version_ 1797530424772132864
author Ligia M. Watanabe
Anderson M. Navarro
Lucia A. Seale
author_facet Ligia M. Watanabe
Anderson M. Navarro
Lucia A. Seale
author_sort Ligia M. Watanabe
collection DOAJ
description Obesity is among the most alarming health concerns, impacting public health and causing a socioeconomic challenge, especially in developing countries like Brazil, where approximately one quart of the population presents obesity. As an established risk factor for numerous comorbidities with a multifactorial etiology, obesity is a consequence of energy-dense overfeeding, however with significant undernourishment, leading to excessive adipose tissue accumulation and dysfunction, dyslipidemia, and micronutrient deficiencies. About 60% of patients with obesity take statins, a cholesterol-lowering medication, to curb dyslipidemia, with ~10% of these patients presenting various myopathies as side effects. Statins act upon the rate-limiting enzyme of cholesterol biosynthesis in the liver, which is a pathway providing intermediates to the synthesis of selenoproteins, i.e., enzymes containing the micronutrient selenium. Statins have been postulated to negatively impact selenoprotein synthesis, particularly in conditions of selenium deficiency, and potentially implicated in the myopathies occurring as side effects of statins. The Brazilian population is prone to selenium deficiency, hence could be considered more susceptible to statin side effects. This review examines the specific consequences to the Brazilian population of the harmful intersection between obesity development and concomitant micronutrient deficiencies, particularly selenium, combined with statin treatment in the context of nutrition in Brazil.
first_indexed 2024-03-10T10:28:45Z
format Article
id doaj.art-e166ed04d5714a429981d1362f97a535
institution Directory Open Access Journal
issn 2072-6643
language English
last_indexed 2024-03-10T10:28:45Z
publishDate 2021-06-01
publisher MDPI AG
record_format Article
series Nutrients
spelling doaj.art-e166ed04d5714a429981d1362f97a5352023-11-21T23:51:05ZengMDPI AGNutrients2072-66432021-06-01136202710.3390/nu13062027Intersection between Obesity, Dietary Selenium, and Statin Therapy in BrazilLigia M. Watanabe0Anderson M. Navarro1Lucia A. Seale2Department of Health Sciences, Division of Nutrition and Metabolism, Ribeirão Preto Medical School, University of São Paulo—FMRP/USP, Ribeirão Preto 14040-900, SP, BrazilDepartment of Health Sciences, Division of Nutrition and Metabolism, Ribeirão Preto Medical School, University of São Paulo—FMRP/USP, Ribeirão Preto 14040-900, SP, BrazilPacific Biosciences Research Center, School of Ocean and Earth Science and Technology, University of Hawaii at Manoa, Honolulu, HI 96822, USAObesity is among the most alarming health concerns, impacting public health and causing a socioeconomic challenge, especially in developing countries like Brazil, where approximately one quart of the population presents obesity. As an established risk factor for numerous comorbidities with a multifactorial etiology, obesity is a consequence of energy-dense overfeeding, however with significant undernourishment, leading to excessive adipose tissue accumulation and dysfunction, dyslipidemia, and micronutrient deficiencies. About 60% of patients with obesity take statins, a cholesterol-lowering medication, to curb dyslipidemia, with ~10% of these patients presenting various myopathies as side effects. Statins act upon the rate-limiting enzyme of cholesterol biosynthesis in the liver, which is a pathway providing intermediates to the synthesis of selenoproteins, i.e., enzymes containing the micronutrient selenium. Statins have been postulated to negatively impact selenoprotein synthesis, particularly in conditions of selenium deficiency, and potentially implicated in the myopathies occurring as side effects of statins. The Brazilian population is prone to selenium deficiency, hence could be considered more susceptible to statin side effects. This review examines the specific consequences to the Brazilian population of the harmful intersection between obesity development and concomitant micronutrient deficiencies, particularly selenium, combined with statin treatment in the context of nutrition in Brazil.https://www.mdpi.com/2072-6643/13/6/2027obesityseleniumBrazilstatins
spellingShingle Ligia M. Watanabe
Anderson M. Navarro
Lucia A. Seale
Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
Nutrients
obesity
selenium
Brazil
statins
title Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
title_full Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
title_fullStr Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
title_full_unstemmed Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
title_short Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil
title_sort intersection between obesity dietary selenium and statin therapy in brazil
topic obesity
selenium
Brazil
statins
url https://www.mdpi.com/2072-6643/13/6/2027
work_keys_str_mv AT ligiamwatanabe intersectionbetweenobesitydietaryseleniumandstatintherapyinbrazil
AT andersonmnavarro intersectionbetweenobesitydietaryseleniumandstatintherapyinbrazil
AT luciaaseale intersectionbetweenobesitydietaryseleniumandstatintherapyinbrazil